6533b826fe1ef96bd12850da
RESEARCH PRODUCT
C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis
Antonio PintoAntonino Tuttolomondosubject
Pathologymedicine.medical_specialtyInflammationConstriction PathologicDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansbiologyC-reactive protein intracranial atherosclerosisbusiness.industryIschemic strokesC-reactive proteinAtherosclerosismedicine.diseaseThrombosisInflammatory biomarkersC-Reactive Proteinbiology.proteinPlatelet aggregation inhibitorNeurology (clinical)Intracranial Atherosclerosismedicine.symptombusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgerydescription
C-reactive protein (CRP) and other inflammatory biomarkers can indicate both the severity and extent of atherosclerosis, reflecting the inflammatory nature of the disease process.1 Atherogenesis begins with an inflammatory response to vascular injury with cells and mediators initiating the healing response and later inducing growth of atherosclerotic plaques. Inflammation then increases plaque instability, promoting rupture, fissuring, or erosion—the pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-12 | Neurology |